Congenital myasthenic syndrome in Turkey: clinical and genetic features in the long-term follow-up of patients

  • Gülen Gül MertEmail author
  • Neslihan Özcan
  • Özlem Hergüner
  • Şakir Altunbaşak
  • Faruk Incecik
  • Atıl Bişgin
  • Serdar Ceylaner
Original article


Congenital Myasthenic Syndromes (CMS) are rare disorders that occur as a result of defects in the structure and in the function of neuromuscular junctions. Molecular genetic diagnosis is important to select the most suitable therapeutic option and treatment. Eight patients with congenital myasthenic syndromes who presented to the Çukurova University Pediatric Neurology Department Outpatient Clinic between June 2015 and May 2018 were reviewed. Mutations in the acetylcholine receptor (subunits in epsilon) (CHRNE) in three and mutations in the collagenic tail of endplate acetylcholinesterase (COLQ) gene in five patients were identified; p.W148 mutation was detected to be homozygous in four, c.1169A > G novel mutation in COLQ gene was homozygous in one, c452_454delAGG mutation was homozygous in the other patient, IVS7 + 2T > C(c.802 + 2T > C) mutation was homozygous in a patient and compound heterozygous mutations of c.865C > T(p.Leu289Phe) and c.872C > G(p.A2916)(p.Arg291Gly) in the CHRNE gene in the last patient. The parents of all the evaluated patients were consanguineous. Ptosis, ophthalmoplegia, generalized hypotonia, bulbar weakness, and respiratory crisis were the main findings at the time of presentation. Pyridostigmine is the first-line drug therapy in primary AChR deficiency. Beta adrenergic agonists, ephedrine, and albuterol are the other treatment options for CMS subtypes caused by mutations in COLQ. This study points out the genetic and phenotypic features of CMS patients in the Turkish population and it also reports previously unreported mutations in the literature. CHRNE and COLQ gene mutations are common in the Turkish population. Patients can get serious benefits and recover after the treatment. The treatment should be planned according to genetic tests and clinical findings.


Congenital myasthenic syndromes CHRNE COLQ Neuromuscular junction 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from the parents or legal guardians of each participant included in the study.


  1. 1.
    Engel AG (2018) Congenital myasthenic syndromes. Curr Neurol Neurosci Rep 46:2–11Google Scholar
  2. 2.
    Müller JS, Mihaylova V, Abicht A, Lochmüller H (2007) Congenital myasthenic syndromes: spotlight on genetic defects of neuromuscular transmission. Expert Rev Mol Med 9:1–20CrossRefGoogle Scholar
  3. 3.
    Parr JR, Andrew MJ, Finnis M, Beeson D, Vincent A, Jayawant S (2014) How common is childhood myasthenia? The UK incidence and prevalence of autoimmune and congenital myasthenia. Arch Dis Child 99:5–9CrossRefGoogle Scholar
  4. 4.
    Engel AG, Shen X-M, Selcen D, Sine SM (2015) Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. Lancet Neurol 14:420–434CrossRefGoogle Scholar
  5. 5.
    Engel AG (2014) Congenital myasthenic syndromes. In: Katirji B, Kaminski HJ, Ruff RL (eds) Neuromuscular disorders in clinical practice. Springer, New York, pp 1073–1090Google Scholar
  6. 6.
    Rodríguez Cruz PM, Palace J, Beeson D (2014) Inherited disorders of the neuromuscular junction: an update. J Neurol 261:2234–2243CrossRefGoogle Scholar
  7. 7.
    McMacken G, Abicht A, Evangelista T, Spendiff S, Lochmüller H (2017) The increasing genetic and phenotypical diversity of congenital myasthenic syndromes. Neuropediatrics 48:294–308CrossRefGoogle Scholar
  8. 8.
    Abicht A, Dusl M, Gallenmüller C et al (2012) Congenital myasthenic syndromes: achievements and limitations of phenotype-guided gene-after-gene sequencing in diagnostic practice: a study of 680 patients. Hum Mutat 33:1474–1484CrossRefGoogle Scholar
  9. 9.
    Shieh PB, Oh SJ (2018) Congenital myasthenic syndromes. Neurol Clin 36:367–378CrossRefGoogle Scholar
  10. 10.
    Das AS, Agamanolis DP, Cohen BH (2014) Use of next-generation sequencing as a diagnostic tool for congenital myasthenic syndrome. Pediatr Neurol 51:717–720CrossRefGoogle Scholar
  11. 11.
    Abicht A, Müller J S, Lochmüller H (2003) Congenital myasthenic syndromes. 2003 May 9 [Updated 2016 Jul 14]. In: Adam MP, Ardinger HH, Pagon RA et al. GeneReviews®. University of Washington, Seattle; 1993–2017Google Scholar
  12. 12.
    Aharoni S, Sadeh M, Shapira Y, Edvardson S, Daana M, Dor-Wollman T et al (2017) Congenital myasthenic syndrome in Israel: genetic and clinical characterization. Neuromuscul Disord 27:136–140CrossRefGoogle Scholar
  13. 13.
    Engel AG (2018) Genetic basis and phenotypic features of congenital myasthenic syndromes. Handb Clin Neurol. 148:565–589CrossRefGoogle Scholar
  14. 14.
    Guven A, Demirci M, Anlar B (2012) Recurrent COLQ mutation in congenital myasthenic syndrome. Pediatr Neurol 46:253–256CrossRefGoogle Scholar
  15. 15.
    Yis U, Becker K, Kurul SH et al (2017) Genetic landscape of congenital myasthenic syndromes from Turkey: novel mutations and clinical insights. J Child Neurol 32:759–765CrossRefGoogle Scholar
  16. 16.
    Ohno K, Milone M, Shen X et al (2003) A frameshift mutation in CHRNE unmasks skipping of the preceding exon. Hum Mol Genet 12:3055–3066CrossRefGoogle Scholar
  17. 17.
    Richard P, Gaudon K, Fournier E et al (2007) A synonymous CHRNE mutation responsible for an aberrant splicing leading to congenital myasthenic syndrome. Neuromuscul Disord 17:409–414CrossRefGoogle Scholar
  18. 18.
    Ohno K, Quiram P, Milone M, Wang HL, Harper MC, Pruitt JN 2nd et al (1997) Congenital myasthenic syndromes due to heteroallelic nonsense/missense mutations in the acetylcholine receptor ε subunit gene: identification and functional characterization of six new mutations. Hum Mol Genet 6:753–766CrossRefGoogle Scholar
  19. 19.
    Beeson D, Hantai D, Lochmüller H, Engel AG (2005) 126th International Workshop: congenital myasthenic syndromes, 24–26 September 2004, Naarden, the Netherlands. Neuromuscul Disord 15(7):498–512CrossRefGoogle Scholar
  20. 20.
    Estephan EP, Sobreira CFDR, Dos Santos ACJ, Tomaselli PJ, Marques W Jr, Ortega RPM et al (2018) A common CHRNE mutation in Brazilian patients with congenital myasthenic syndrome. J Neurol 265:708–713CrossRefGoogle Scholar
  21. 21.
    Durmus H, Shen X, Serdaroglu-Oflazer P, Kara B, Gulsen-Parman Y, Coskun Ozdemir C et al (2018) Congenital myasthenic syndromes in Turkey: clinical clues and prognosis with long term follow-up. Neuromuscul Disord 28:315–322CrossRefGoogle Scholar
  22. 22.
    Engel AG, Ohno K, Milone M, Sine SM (1998) Congenital myasthenic syndromes: new insights from molecular genetic and patch-clamp studies. Ann N Y Acad Sci 841:140–156CrossRefGoogle Scholar
  23. 23.
    Ohno K, Brengman J, Tsujino A, Engel AG (1998) Human endplate acetylcholinesterase deficiency caused by mutations in the collagen-like tail subunit (ColQ) of the asymmetric enzyme. Proc Natl Acad Sci USA 95:9654–9659CrossRefGoogle Scholar
  24. 24.
    Shapira YA, Sadeh ME, Bergtraum MP, Tsujino A, Ohno K, Shen XM et al (2002) Three novel COLQ mutations and variation of phenotypic expressivity due to G240X. Neurology 58:603–609CrossRefGoogle Scholar
  25. 25.
    Muller JS, Petrova S, Kiefer R, Stucka R, Konig C, Baumeister SK et al (2004) Synaptic congenital myasthenic syndrome in three patients due to a novel missense mutation (T441A) of the COLQ gene. Neuropediatrics 35:183–189CrossRefGoogle Scholar
  26. 26.
    Bestue-Cardiel M, Saenz de Cabezon-Alvarez A, Capablo-Liesa JL, Lopez-Pison J, Pena-Segura JL, Martin-Martinez J et al (2005) Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. Neurology 65:144–146CrossRefGoogle Scholar
  27. 27.
    Donger C, Krejci E, Serradell AP, Eymard B, Bon S, Nicole S et al (1998) Mutation in the human acetylcholinesterase-associated collagen gene, COLQ, is responsible for congenital myasthenic syndrome with end-plate acetylcholinesterase deficiency (Type Ic). Am J Hum Genet 63:967–975CrossRefGoogle Scholar
  28. 28.
    Mihaylova V, Müller JS, Sanchez JJ et al (2008) Clinical and molecular genetic findings in COLQ-mutant congenital myasthenic syndromes. Brain 131:747–759CrossRefGoogle Scholar
  29. 29.
    Shigaki K, Nicolle D, Krejci E et al (2003) Two novel mutations in the COLQ gene cause endplate acetylcholinesterase deficiency. Neuromuscul Disord 13:236–244CrossRefGoogle Scholar
  30. 30.
    Ohno K, Anlar B, Ozdirim E, Brengman JM, DeBleecker JL, Engel AG (1998) Myasthenic syndromes in Turkish kinships due to mutations in the acetylcholine receptor. Ann Neurol 44:234–241CrossRefGoogle Scholar
  31. 31.
    Witoonpanich R, Pulkes T, Dejthevaporn C et al (2011) Phenotypic heterogeneity in a large Thai slow-channel congenital myasthenic syndrome kinship. Neuromuscul Disord 21:214–218CrossRefGoogle Scholar
  32. 32.
    Schara U, Barisic N, Deschauer M, Lindberg C, Straub V, Strigl-Pill N et al (2009) Ephedrine therapy in eight patients with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscul Disord 19:828–832CrossRefGoogle Scholar
  33. 33.
    Fukudome T, Ohno K, Brengman JM, Engel AG (1998) Quinidine normalizes the open duration of slow-channel mutants of the acetylcholine receptor. NeuroReport 9:1907–1911CrossRefGoogle Scholar

Copyright information

© Belgian Neurological Society 2019

Authors and Affiliations

  • Gülen Gül Mert
    • 1
    Email author
  • Neslihan Özcan
    • 1
  • Özlem Hergüner
    • 1
  • Şakir Altunbaşak
    • 1
  • Faruk Incecik
    • 1
  • Atıl Bişgin
    • 2
  • Serdar Ceylaner
    • 3
  1. 1.Department of Pediatrics, Division of Pediatric NeurologyCukurova UniversityAdanaTurkey
  2. 2.Department of Medical GeneticsCukurova University Faculty of MedicineAdanaTurkey
  3. 3.Intergen Genetic LaboratoryAnkaraTurkey

Personalised recommendations